Virtual Incision Funding, Investors & Competitors

Virtual Incision has raised $129M across 6 funding rounds, most recently a $30M Series C in September 2023.

Last Virtual Incision funding round

$30M

Series C · Sep 2023

Cumulative funding Virtual Incision raised

$129M

across 6 funding rounds

Key investors in Virtual Incision

  • Bluestem Capital
  • PrairieGold Venture Partners
  • Baird Capital
  • Endeavour Vision
  • Arboretum Ventures
  • Sinopharm Capital
  • cultivate(MD)
  • Genesis Innovation Group

Virtual Incision Overview

About Virtual Incision

Virtual Incision is a Lincoln, Nebraska-headquartered medical robotics company developing the MIRA platform, a miniaturized in vivo robotic assistant for minimally invasive surgeries. Initially focused on colon resection procedures, MIRA received FDA clearance in 2024 for soft tissue use, measuring just 27 millimeters in diameter. The device supports precise intracorporeal manipulation during laparoscopic operations. Founded in 2006, Virtual Incision collaborates with surgical teams at Mayo Clinic and advances toward broader applications in gynecology and urology.


Founded

2006

HQ

United StatesLincoln, NE

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Virtual Incision Funding History

Virtual Incision has raised a total of $129M across 6 funding rounds.

Virtual Incision's first fundraising round was a $4M seed round in January 2014. The most recent completed round was a $30M Series C in September 2023.

Virtual Incision funding rounds

Virtual Incision funding rounds
DateStageInvestorsRaisedDeal Summary
Sep 2023Series CArboretum Ventures (lead); Bluestem Capital; PrairieGold Venture Partners; Baird Capital; InVivium Capital; Invictum Capital; Endeavour Vision; cultivate(MD)$30MVirtual Incision Corporation develops the MIRA Surgical System, the world’s first miniaturized robotic-assisted surgery (RAS) platform designed to expand access to RAS in routine and high-volume procedures, including those in outpatient and ambulatory surgery centers. The compact miniRAS system fits in a surgical tray, addressing limitations of larger systems, and supports applications like bowel resection and gynecology, with ongoing development for additional general surgery uses. On September 19, 2023, Virtual Incision announced a $30 million extension to its prior $46 million Series C financing, bringing the total Series C to $76 million. The extension was led by existing investors Bluestem Capital, Endeavour Vision, Baird Capital, cultivate(MD) Capital Funds, and PrairieGold Venture Partners, with new investors Arboretum Ventures and InVivium Capital. Arboretum Ventures' participation came from its $268 million Arboretum Ventures VI fund. Concurrently, Tom Shehab from Arboretum Ventures joined the board, and Amy Kobe from InVivium Capital became a board observer. The funding supports operations into 2025, a planned gynecologic clinical study in 2024, development of a smaller minibot iteration with a first-in-human study expected the following year, and a NASA collaboration for telesurgery in space using a modified MIRA on the International Space Station. Recent milestones include completing an IDE clinical study for bowel resection and having a De Novo request under FDA substantive review, positioning for a potential limited U.S. launch upon authorization. Overall, Virtual Incision has raised over $137 million since 2006, with sources citing totals up to $152.14 million across 16 rounds as of 2025, reflecting sustained investor support in a challenging market. The company originated from University of Nebraska collaborations between robotics engineer Shane Farritor and surgeon Dmitry Oleynikov.
Nov 2021Series CBaird Capital (lead); Endeavour Vision (lead); Bluestem Capital$46MVirtual Incision Corporation, a medical device company based in Lincoln, Nebraska, develops miniaturized robots for laparoscopic surgery, with its flagship MIRA Surgical Platform designed as a first-of-its-kind miniaturized in vivo robotic assistant to enable minimally invasive procedures across various care settings. Virtual Incision, formerly Nebraska Surgical Solutions and founded in 2006, focuses on enhancing surgical precision and outcomes in the healthcare industry through its MIRA system, which supports broader adoption of minimally invasive techniques. On November 30, 2021, the company announced a $46 million Series C funding round led by Endeavour Vision and Baird Capital, with participation from returning investor Bluestem Capital and others. The funds are allocated to support regulatory and clinical programs for MIRA commercialization, as well as research and development for a pipeline of mini-robots targeting procedures like colon resection, hernia repair, gallbladder removal, hysterectomy, and sleeve gastrectomy. The MIRA platform aims to transform surgery by providing efficient, effective, and affordable robotic-assisted technology regardless of care site, backed by over 200 patents and applications positioning Virtual Incision to lead innovation in robotic-assisted surgery. Total funding across rounds reached approximately $139M to $152M by various estimates, with this Series C contributing $46M toward advancing the platform beyond initial colon resection applications. Subsequent developments include partnerships like with Nvidia for next-generation robots using synthetic data and simulation, and clinical milestones such as the first hysterectomy with MIRA.
Jan 2020Series BBluestem Capital (lead); PrairieGold Venture Partners; Genesis Innovation Group$20MVirtual Incision is a Lincoln, Nebraska-based surgical robotics company spun out from the University of Nebraska in 2006 by engineers Shane Farritor and surgeon Dmitry Oleynikov. The company develops the MIRA (miniaturized in vivo robotic assistant) platform, a compact two-pound robot designed to enable minimally invasive laparoscopic procedures, particularly colon resections, hernia repairs, and gallbladder removals, transforming open surgeries into less invasive options with shorter recovery times. MIRA's portability allows use across operating rooms without dedicated space, unlike larger competitors. In early 2020, Virtual Incision closed a $20 million Series B+ round led by Bluestem Capital, with participation from PrairieGold Venture Partners, Genesis Innovation Group, and others, incorporating $1 million in prior debt from Bluestem and PrairieGold disclosed in August 2019. This brought total funding since inception to over $50 million, following prior rounds including an $18 million Series B in 2017 co-led by Bluestem and SinoPharm Capital, $11.2 million in 2015, $2 million Series A in 2010, and initial equity in 2006. The proceeds support regulatory filings, including an Investigational Device Exemption with the FDA for a clinical study on MIRA in colon resection surgeries, aiming toward commercialization. The company expanded its Nebraska Innovation Campus headquarters in 2019 for integrated R&D, quality control, and assembly. By 2016, MIRA had performed complex tasks in a living human. Later developments include a $46 million Series C in 2023 extended by $30 million, led by Bluestem Capital and others including new investors Arboretum Ventures and InVivium Capital, funding operations into 2025, gynecologic and general surgery clinical studies, and miniRAS advancements for ambulatory settings.
Dec 2017Series BBluestem Capital (lead); Sinopharm Capital (lead); PrairieGold Venture Partners$18MVirtual Incision Corporation, a Nebraska-based surgical robotics startup spun out from University of Nebraska research, develops a miniaturized robotically assisted surgical device (RASD) for minimally invasive abdominal procedures like colon resection, gallbladder removal, hernia repair, and colectomy. The two-pound robot enters through a single umbilical incision, uses existing surgeon tools, incorporates AI and machine learning for instrument guidance, and requires no dedicated operating room unlike larger competitors weighing up to 2,000 pounds. It promises lower costs, greater mobility, and reduced operating room complexity. The company completed an $18 million Series B funding round on December 15, 2017, co-led by Bluestem Capital and Sinopharm Capital, with participation from PrairieGold Venture Partners and others. Funds support manufacturing, clinical trials, and FDA 510(k) submission for market clearance, targeting approval by late 2019. This followed a $2 million Series A in 2010 and $11.2 million round in 2015, which enabled successful feasibility trials and first-in-human colon resection procedures outside the US in 2016. Founded in 2006 by professors Dmitry Oleynikov (chief medical officer) and Shane Farritor (chief technology officer), Virtual Incision aims to provide cost-effective alternatives to expensive robotic systems, potentially shortening hospital stays and lowering capital expenses by an order of magnitude.
Aug 2015Series ABluestem Capital (lead); PrairieGold Venture Partners$11MVirtual Incision, a surgical robotics company spun out from the University of Nebraska, raised $11.2 million in a 2015 funding round led by Bluestem Capital with participation from PrairieGold Venture Partners. The round was oversubscribed and supported a feasibility study on the company's miniaturized robotically assisted surgical technology for colon resection procedures. The technology targets lower gastrointestinal diseases including diverticulitis, Crohn's disease, inflammatory bowel disease, and colon cancer, addressing the fastest-growing surgeries in the US at 14% annual growth. The funding backed development of a compact robotic device weighing about two pounds, contrasting with larger systems up to 2,000 pounds that require dedicated operating rooms. Virtual Incision's platform, supported by over 90 patents and 70 comparative medicine studies, aims for less invasive general surgeries like gallbladder removal, hernia repair, and colectomy. Bluestem Capital praised the team's capital efficiency and medtech expertise for potential disruption in patient care and healthcare systems.
Jan 2014Seed-$4M-

Who has invested in Virtual Incision?

10 investors have backed Virtual Incision across its funding rounds, including Bluestem Capital, PrairieGold Venture Partners, Baird Capital, Endeavour Vision, Arboretum Ventures and Sinopharm Capital.

Lead investors include Arboretum Ventures, Baird Capital, Endeavour Vision, Bluestem Capital and Sinopharm Capital.


Virtual Incision Investors

Investors in Virtual Incision by funding rounds participated
InvestorHQRoundsRoleFirst check
Bluestem CapitalUnited StatesSioux Falls, SD5LeadAug 2015
PrairieGold Venture PartnersUnited StatesSioux Falls, SD4ParticipantAug 2015
Baird CapitalUnited StatesMilwaukee, WI2LeadNov 2021
Endeavour VisionSwitzerlandGeneva2LeadNov 2021
Sinopharm CapitalChinaShanghai1LeadDec 2017
Genesis Innovation GroupUnited StatesHolland, MI1ParticipantJan 2020
Arboretum VenturesUnited StatesAnn Arbor, MI1LeadSep 2023
InVivium CapitalUnited StatesChicago, IL1ParticipantSep 2023

This data is available for Pro users. Sign up to see all 10 Virtual Incision investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Virtual Incision Competitors

Virtual Incision competitors include listed companies like Siemens, Johnson & Johnson, Roche and Thermo Fisher Scientific, and private ones like Biosplice Therapeutics and Neuralink.

Public and private companies comparable to Virtual Incision
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
SiemensGermanyGermanyPublicly listed$91B$15B$234B2.9x
Johnson & JohnsonUnited StatesUnited StatesPublicly listed$94B$40B$651B6.8x
RocheSwitzerlandSwitzerlandPublicly listed$77B$26B$351B4.9x
Thermo Fisher ScientificUnited StatesUnited StatesPublicly listed$45B$11B$243B6.0x
Biosplice TherapeuticsUnited StatesSan Diego, CAPrivate--$12B-
NeuralinkUnited StatesUnited StatesPrivate--$9B-

Virtual Incision Public Comps

Virtual Incision is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Schneider Electric, Abbott, ABB, Hitachi and Danaher.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Samsung$243B$67B4.4x2.4x15.8x4.4x
Johnson & Johnson$94B$40B7.2x6.8x17.0x18.3x
Roche$77B$26B5.0x4.9x14.6x12.4x
Thermo Fisher Scientific$45B$11B6.3x6.0x26.8x23.6x
Siemens$91B$15B3.0x2.9x18.1x15.7x
Schneider Electric$46B$9.5B4.3x3.9x21.0x18.4x
Abbott$44B$12B4.6x4.2x17.4x15.8x
ABB$33B$6.9B5.4x4.9x25.9x22.6x

This data is available for Pro users. Sign up to see all Virtual Incision competitors and their valuation data.

Start Free Trial

Common questions about Virtual Incision

When was Virtual Incision founded?Virtual Incision was founded in 2006.
Where is Virtual Incision headquartered?Virtual Incision is headquartered in Lincoln, NE, United States.
Is Virtual Incision publicly listed?No, Virtual Incision is a private, VC-backed company.
How much funding has Virtual Incision raised?Virtual Incision has raised $129M across 6 funding rounds.
What was Virtual Incision's last funding round?Virtual Incision's last funding round was a $30M Series C in September 2023, led by Arboretum Ventures.
Who are Virtual Incision's investors?Virtual Incision's investors include Bluestem Capital, PrairieGold Venture Partners, Baird Capital, Endeavour Vision, Sinopharm Capital, Genesis Innovation Group, Arboretum Ventures, InVivium Capital, Invictum Capital and cultivate(MD).
Which companies are comparable to Virtual Incision?Companies comparable to Virtual Incision include Siemens, Johnson & Johnson, Roche, Thermo Fisher Scientific, Biosplice Therapeutics and Neuralink.

See companies similar to Virtual Incision

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial